Avenue Therapeutics Inc (ATXI)
OTHER OTC:ATXI
Total Valuation
Avenue Therapeutics has a market cap or net worth of $1.48M. The enterprise value is -$1.37M.
Market Cap$1.48M
Enterprise Value-$1.37M
Share Statistics
Avenue Therapeutics has 3,294,635 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,294,635
Owned by Insiders10.32%
Owned by Institutions5.69%
Financial Efficiency
Avenue Therapeutics’s return on equity (ROE) is -1.59 and return on invested capital (ROIC) is -187.13%.
Return on Equity (ROE)-1.59
Return on Assets (ROA)-0.99
Return on Invested Capital (ROIC)-187.13%
Return on Capital Employed (ROCE)-1.79
Revenue Per Employee702.00K
Profits Per Employee-1.45M
Employee Count2
Asset Turnover0.48
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Avenue Therapeutics is ―. Avenue Therapeutics’s PEG ratio is -0.22.
PE Ratio―
PS Ratio1.52
PB Ratio1.16
Price to Fair Value1.16
Price to FCF-1.16
Price to Operating Cash Flow-0.77
PEG Ratio-0.22
Income Statement
In the last 12 months, Avenue Therapeutics had revenue of 1.40M and earned -2.91M in profits. Earnings per share was -0.93.
Revenue1.40M
Gross Profit1.40M
Operating Income-3.29M
Pretax Income-2.95M
Net Income-2.91M
EBITDA-3.29M
Earnings Per Share (EPS)-0.93
Cash Flow
In the last 12 months, operating cash flow was -1.83M and capital expenditures 0.00, giving a free cash flow of -1.83M billion.
Operating Cash Flow-1.83M
Free Cash Flow-1.83M
Free Cash Flow per Share-0.56
Dividends & Yields
Avenue Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change73.08%
50-Day Moving Average0.24
200-Day Moving Average0.53
Relative Strength Index (RSI)72.74
Average Volume (3m)2.90K
Important Dates
Avenue Therapeutics upcoming earnings date is Nov 17, 2025, TBA (Confirmed).
Last Earnings DateAug 18, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date―
Financial Position
Avenue Therapeutics as a current ratio of 2.60, with Debt / Equity ratio of 0.00%
Current Ratio2.60
Quick Ratio2.60
Debt to Market Cap0.00
Net Debt to EBITDA0.87
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Avenue Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Avenue Therapeutics EV to EBITDA ratio is 0.22, with an EV/FCF ratio of 0.40.
EV to Sales-0.52
EV to EBITDA0.22
EV to Free Cash Flow0.40
EV to Operating Cash Flow0.40
Balance Sheet
Avenue Therapeutics has $2.85M in cash and marketable securities with $0.00 in debt, giving a net cash position of $2.85M billion.
Cash & Marketable Securities$2.85M
Total Debt$0.00
Net Cash$2.85M
Net Cash Per Share$0.87
Tangible Book Value Per Share$0.59
Margins
Gross margin is 0.00%, with operating margin of -219.59%, and net profit margin of -207.19%.
Gross Margin0.00%
Operating Margin-219.59%
Pretax Margin-207.19%
Net Profit Margin-207.19%
EBITDA Margin-234.05%
EBIT Margin-234.05%
Analyst Forecast
The average price target for Avenue Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast89.68%